Literature DB >> 25770019

Expression of CD73 and A2A receptors in cells from subjects with obesity and type 2 diabetes mellitus.

Juan M Guzman-Flores1, Nancy Cortez-Espinosa1, Juan D Cortés-Garcia1, Juan M Vargas-Morales2, Yolanda G Cataño-Cañizalez1, Jaime G Rodríguez-Rivera3, Diana P Portales-Perez4.   

Abstract

Regulatory T cells have various mechanisms to suppress the inflammatory response, among these, the modulation of the microenvironment through adenosine and with the participation of CD39, CD73 and A2A. The aim of this study was to assess the expression of CD73 and A2A in immune cells and the effect of activation of A2A by an adenosine analogue on apoptosis in patients with obesity and type 2 diabetes mellitus (T2D). CD73 and A2A expression were analyzed by flow cytometry in lymphocyte subpopulations from patients with obesity (n = 22), T2D (n = 22), and healthy subjects (n = 20). Lymphocytes were treated with the selective A2A antagonist (ZM241385) or the selective A2A agonist (CGS21680), and apoptotic cells were detected by Annexin V. We found an increased expression of CD39 coupled to a decrease in CD73 in the patient groups with obesity and T2D compared to the control group in the different studied lymphocyte subpopulations. A2A expression was found to be increased in different subpopulations of lymphocytes from T2D patients. We also detected positive correlations between CD39+ cells and age and BMI. Meanwhile, CD73+ cells showed negative correlations with age, WHR, BMI, FPG, HbAc1, triglycerides and cholesterol. Moreover, an increase in the percentage of apoptotic cells from T2D patients with regard to the groups with obesity and control was observed. In addition, the CD8+ T cells of patients with T2D exhibited decreased apoptosis when treated with the A2A agonist. In conclusion, our data suggest a possible role for CD73 and A2A in inflammation observed in patients with T2D and obesity mediated via apoptosis.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Apoptosis; Diabetes type 2; Inflammation; Obesity; Regulatory T cells

Mesh:

Substances:

Year:  2015        PMID: 25770019     DOI: 10.1016/j.imbio.2015.02.007

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  5 in total

1.  Changes in CD73, CD39 and CD26 expression on T-lymphocytes of ANCA-associated vasculitis patients suggest impairment in adenosine generation and turn-over.

Authors:  Lovis Kling; Urs Benck; Annette Breedijk; Lisa Leikeim; Marianne Heitzmann; Stefan Porubsky; Bernhard K Krämer; Benito A Yard; Anna-Isabelle Kälsch
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

2.  CD73 Rather Than CD39 Is Mainly Involved in Controlling Purinergic Signaling in Calcified Aortic Valve Disease.

Authors:  Igor Kudryavtsev; Maria Serebriakova; Ekaterina Zhiduleva; Patimat Murtazalieva; Vladislav Titov; Anna Malashicheva; Anastasya Shishkova; Daria Semenova; Olga Irtyuga; Dmitry Isakov; Lubov Mitrofanova; Olga Moiseeva; Alexey Golovkin
Journal:  Front Genet       Date:  2019-07-25       Impact factor: 4.599

3.  Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.

Authors:  Victor Manuel Ruiz-Rodríguez; Eneida Turiján-Espinoza; Jaime Arturo Guel-Pañola; Mariana Haydee García-Hernández; José de Jesús Zermeño-Nava; Nallely López-López; Sofia Bernal-Silva; Esther Layseca-Espinosa; Ezequiel M Fuentes-Pananá; Ana María Estrada-Sánchez; Diana Patricia Portales-Pérez
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

Review 4.  The involvement of purinergic signalling in obesity.

Authors:  Geoffrey Burnstock; Daniela Gentile
Journal:  Purinergic Signal       Date:  2018-04-04       Impact factor: 3.765

5.  Nitazoxanide Exerts Immunomodulatory Effects on Peripheral Blood Mononuclear Cells from Type 2 Diabetes Patients.

Authors:  Mauricio Castillo-Salazar; Fausto Sánchez-Muñoz; Rashidi Springall Del Villar; Gabriel Navarrete-Vázquez; Adrián Hernández-DiazCouder; Carlos Mojica-Cardoso; Sara García-Jiménez; Cairo Toledano-Jaimes; Germán Bernal-Fernández
Journal:  Biomolecules       Date:  2021-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.